Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

Hadassah Medical Center: Mishani Eyal

Last updated June 2021 - Hadassah Medical Center

List of Publications

(1) Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med 2020;61(4):527-532.

(2) Shamni O, Grievink H, Itamar B, Mishani E, Abourbeh G. Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation–Positive NSCLC. Mol Imaging Biol 2019;21(4):696-704.

(3) Shamni O, Nebeling B, Grievink H, Mishani E. Fine-tuning of the automated [18F]PSMA-1007 radiosynthesis. J Label Compd Radiopharm 2019;62(6):252-258.

(4) Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, et al. 68 Ga-labeled prostate-specific membrane antigen is a novel PET/CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study. J Nucl Med 2019;60(2):185-191.

(5) Dondi M, Torres L, Marengo M, Massardo T, Mishani E, Van Zyl Ellmann A, et al. Comprehensive Auditing in Nuclear Medicine Through the International Atomic Energy Agency Quality Management Audits in Nuclear Medicine (QUANUM) Program. Part 1: the QUANUM Program and Methodology. Semin Nucl Med 2017;47(6):680-686.

(6) Dondi M, Torres L, Marengo M, Massardo T, Mishani E, Van Zyl Ellmann A, et al. Comprehensive Auditing in Nuclear Medicine Through the International Atomic Energy Agency Quality Management Audits in Nuclear Medicine Program. Part 2: Analysis of Results. Semin Nucl Med 2017;47(6):687-693.

(7) Petrulli JR, Hansen SB, Abourbeh G, Yaqub M, Bahce I, Holden D, et al. A multi species evaluation of the radiation dosimetry of [11C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor. Nucl Med Biol 2017;47:56-61.

(8) Weiss O, Kaufman R, Mishani E, Inbal A. Ocular vessel patterning in zebrafish is indirectly regulated by Hedgehog signaling. Int J Dev Biol 2017;61(3-5):277-284.

(9) Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes. Progress in Biomedical Optics and Imaging - Proceedings of SPIE; 2017.

(10) Weinstein AM, Freedman N, Greif J, Yemini Z, Mishani E, London E, et al. Negative association of pretreatment cigarette use with smoking-induced striatal dopamine release in smokers receiving bupropion treatment. Am J Addict 2016;25(6):486-492.

(11) Motiei M, Dreifuss T, Betzer O, Panet H, Popovtzer A, Santana J, et al. Differentiating between Cancer and Inflammation: A Metabolic-Based Method for Functional Computed Tomography Imaging. ACS Nano 2016;10(3):3469-3477.

(12) Dissoki S, Abourbeh G, Salnikov O, Mishani E, Jacobson O. PET Molecular Imaging of Angiogenesis with a Multiple Tyrosine Kinase Receptor-Targeted Agent in a Rat Model of Myocardial Infarction. Mol Imaging Biol 2015;17(2):222-230.

(13) Abourbeh G, Itamar B, Salnikov O, Beltsov S, Mishani E. Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [11C]erlotinib PET. EJNMMI Res 2015;5(1).

(14) Orevi M, Freedman N, Mishani E, Bocher M, Jacobson O, Krausz Y. Localization of parathyroid adenoma by 11C-Choline PET/CT preliminary results. Clin Nucl Med 2014;39(12):1033-1038.

(15) Jacobson O, Abourbeh G, Tsvirkun D, Mishani E. Rat Imaging and In Vivo Stability Studies using [11C]-Dimethyl-Diphenyl Ammonium, a Candidate Agent for PET-Myocardial Perfusion Imaging. Nucl Med Biol 2013;40(8):967-973.

(16) Kesner AL, Abourbeh G, Mishani E, Chisin R, Tshori S, Freedman N. Gating, enhanced gating, and beyond: Information utilization strategies for motion management, applied to preclinical PET. EJNMMI Res 2013;3(1):1-15.

(17) Kepe V, Moghbel MC, Långströmd B, Zaidi H, Vinters HV, Huang S-, et al. Amyloid-β positron emission tomography imaging probes: A critical review. J Alzheimer's Dis 2013;36(4):613-631.

(18) Ilovich O, Abourbeh G, Bocher M, Freedman N, Billauer H, Dotan S, et al. Structure-activity relationship and preclinical evaluation of carbon-11-labeled ammonium salts as PET-myocardial perfusion imaging agents. Mol Imaging Biol 2012;14(5):625-636.

(19) Orevi M, Klein M, Mishani E, Chisin R, Freedman N, Gofrit ON. 11C-acetate PET/CT in bladder urothelial carcinoma: Intraindividual comparison with 11C-choline. Clin Nucl Med 2012;37(4):e67-e72.

(20) Abourbeh G, Shir A, Mishani E, Ogris M, Rödl W, Wagner E, et al. PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors. IUBMB Life 2012;64(4):324-330.

(21) Gruzman A, Elgart A, Viskind O, Billauer H, Dotan S, Cohen G, et al. Antihyperglycaemic activity of 2,4:3,5-dibenzylidene-D-xylose-diethyl dithioacetal in diabetic mice. J Cell Mol Med 2012;16(3):593-603.

(22) Krausz Y, Rubinstein R, Appelbaum L, Mishani E, Orevi M, Fraenkel M, et al. Ga-68 DOTA-NOC uptake in the pancreas: Pathological and physiological patterns. Clin Nucl Med 2012;37(1):57-62.

(23) Magenheim J, Ilovich O, Lazarus A, Klochendler A, Ziv O, Werman R, et al. Blood vessels restrain pancreas branching, differentiation and growth. Development (Cambridge) 2011;138(21):4743-4752.

(24) Dissoki S, Hagooly A, Elmachily S, Mishani E. Labeling approaches for the GE11 peptide, an epidermal growth factor receptor biomarker. J Label Compd Radiopharm 2011;54(11):693-701.

(25) Lazarus A, Del-Moral PM, Ilovich O, Mishani E, Warburton D, Keshet E. A perfusion-independent role of blood vessels in determining branching stereotypy of lung airways. Development (Cambridge) 2011;138(11):2359-2368.

(26) Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: Comparison with 111In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol 2011;13(3):583-593.

(27) Ilovich O, Billauer H, Dotan S, Freedman NMT, Bocher M, Mishani E. Novel and simple carbon-11-labeled ammonium salts as pet agents for myocardial perfusion imaging. Mol Imaging Biol 2011;13(1):128-139.

(28) Sand FW, Hörnblad A, Johansson JK, Lorén C, Edsbagge J, Ståhlberg A, et al. Growth-limiting role of endothelial cells in endoderm development. Dev Biol 2011;352(2):267-277.

(29) Pantaleo MA, Mishani E, Nanni C, Landuzzi L, Boschi S, Nicoletti G, et al. Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Mol Imaging Biol 2010;12(6):616-625.

(30) Cohen O, Mishani E, Rozen S. From carboxylic acids to the trifluoromethyl group using BrF3. Tetrahedron 2010;66(20):3579-3582.

(31) Ilovich O, Billauer H, Dotan S, Mishani E. Labeled 3-aryl-4-indolylmaleimide derivatives and their potential as angiogenic PET biomarkers. Bioorg Med Chem 2010;18(2):612-620.

(32) Mishani E, Hagooly A. Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer. J Nucl Med 2009;50(8):1199-1202.

(33) Ruvinsky I, Katz M, Dreazen A, Gielchinsky Y, Saada A, Freedman N, et al. Mice deficient in ribosomal protein S6 phosphorylation suffer from muscle weakness that reflects a growth defect and energy deficit. PLoS ONE 2009;4(5).

(34) Dissoki S, Eshet R, Billauer H, Mishani E. Modified PEG-anilinoquinazoline derivatives as potential EGFR PET agents. J Label Compd Radiopharm 2009;52(2):41-52.

(35) Afergan E, Epstein H, Koroukhov N, Klein M, Litchi A, Mishani E, et al. Biodistribution and imaging studies of 67Ga-labeled liposomes in rabbits with a vascular injury. J Drug Deliv Sci Technol 2009;19(4):263-268.

(36) Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des 2008;14(28):2983-2998.

(37) Ben-Daniel R, Deuther-Conrad W, Scheunemann M, Steinbach J, Brust P, Mishani E. Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter. Bioorg Med Chem 2008;16(12):6364-6370.

(38) Ilovich O, Jacobson O, Aviv Y, Litchi A, Chisin R, Mishani E. Formation of fluorine-18 labeled diaryl ureas-labeled VEGFR-2/PDGFR dual inhibitors as molecular imaging agents for angiogenesis. Bioorg Med Chem 2008;16(8):4242-4251.

(39) Jacobson O, Mishani E. [11C]-dimethylamine as a labeling agent for PET biomarkers. Appl Radiat Isot 2008;66(2):188-193.

(40) Even-Sapir E, Mishani E, Flusser G, Metser U. 18F-Fluoride Positron Emission Tomography and Positron Emission Tomography/Computed Tomography. Semin Nucl Med 2007;37(6):462-469.

(41) Dissoki S, Aviv Y, Laky D, Abourbeh G, Levitzki A, Mishani E. The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety-An EGFR putative irreversible inhibitor. Appl Radiat Isot 2007;65(10):1140-1151.

(42) Mishani E, Abourbeh G. Cancer molecular imaging: Radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR). Curr Top Med Chem 2007;7(18):1755-1772.

(43) Shushan A, Ben-Bassat H, Mishani E, Laufer N, Klein BY, Rojansky N. Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertil Steril 2007;87(1):127-135.

(44) Abourbeh G, Dissoki S, Jacobson O, Litchi A, Daniel RB, Laki D, et al. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol 2007;34(1):55-70.

(45) Gofrit ON, Mishani E, Orevi M, Klein M, Freedman N, Pode D, et al. Contribution of 11C-Choline Positron Emission Tomography/Computerized Tomography to Preoperative Staging of Advanced Transitional Cell Carcinoma. J Urol 2006;176(3):940-944.

(46) Jacobson O, Laky D, Carlson KE, Elgavish S, Gozin M, Even-Sapir E, et al. Chiral dimethylamine flutamide derivatives-modeling, synthesis, androgen receptor affinities and carbon-11 labeling. Nucl Med Biol 2006;33(6):695-704.

(47) Levitzki A, Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 2006;75:93-109.

(48) Dissoki S, Laky D, Mishani E. Fluorine-18 labeling of ML04 - Presently the most promising irreversible inhibitor candidate for visualization of EGFR in cancer. J Label Compd Radiopharm 2006;49(6):533-543.

(49) Wald O, Weiss ID, Wald H, Shoham H, Bar-Shavit Y, Beider K, et al. IFN-γ acts on T cells to induce NK cell mobilization and accumulation in target organs. J Immunol 2006;176(8):4716-4729.

(50) Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F- Fluoride PET/CT. J Nucl Med 2006;47(2):287-297.

(51) Jacobson O, Bechor Y, Icar A, Novak N, Birman A, Marom H, et al. Prostate cancer PET bioprobes: Synthesis of [18F]-radiolabeled hydroxyflutamide derivatives. Bioorg Med Chem 2005;13(22):6195-6205.

(52) Freedman NMT, Mishani E, Krausz Y, Weininger J, Lester H, Blaugrund E, et al. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using 11C-L-deprenyl and PET. J Nucl Med 2005;46(10):1618-1624.

(53) Mishani E, Abourbeh G, Jacobson O, Dissoki S, Ben Daniel R, Rozen Y, et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem 2005;48(16):5337-5348.

(54) Barda Y, Cohen N, Lev V, Ben-Aroya N, Koch Y, Mishani E, et al. Backbone metal cyclization: Novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer. Nucl Med Biol 2004;31(7):921-933.

(55) Shaul M, Abourbeh G, Jacobson O, Rozen Y, Laky D, Levitzki A, et al. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem 2004;12(13):3421-3429.

(56) Mishani E, Abourbeh G, Rozen Y, Jacobson O, Laky D, David IB, et al. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: Potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol 2004;31(4):469-476.

(57) Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease: Initial experience with 18F-fluoride PET/CT and comparison between18F-fluoride PET and18F-fluoride PET/CT. J Nucl Med 2004;45(2):272-278.

(58) Ben-David I, Rozen Y, Ortu G, Mishani E. Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride. Appl Radiat Isot 2003;58(2):209-217.

(59) Ortu G, Ben-David I, Rozen Y, Freedman NMT, Chisin R, Levitzki A, et al. Labeled EGFr-TK irreversible inhibitor (ML03): In vitro and in vivo properties, potential as pet biomarker for cancer and feasibility as anticancer drug. Int J Cancer 2002;101(4):360-370.

(60) Mishani E, Ben-David I, Rozen Y. Improved method for the quality assurance of [C-11]choline. Nucl Med Biol 2002;29(3):359-362.

(61) Bonasera TA, Ortu G, Rozen Y, Krais R, Freedman NMT, Chisin R, et al. Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl Med Biol 2001;28(4):359-374.

(62) Bocher M, Chisin R, Parag Y, Freedman N, Meir Weil Y, Lester H, et al. Cerebral activation associated with sexual arousal in response to a pornographic clip: A 15O-H2O PET study in heterosexual men. Neuroimage 2001;14(1 I):105-117.

(63) Bocher M, Mishani E. The contribution of position emission tomography to the treatment of cancer patients. Harefuah 2000;139(1-2):64-67.

(64) Ben-David I, Rechavi D, Mishani E, Rozen S. A novel synthesis of trifluoromethyl ethers via xanthates, utilizing BrF3. J Fluor Chem 1999;97(1-2):75-78.

(65) Mishani E, Lifshits N, Osavistky A, Kaufman J, Ankry N, Tal N, et al. Radiation levels in cyclotron-radiochemistry facility measured by a novel comprehensive computerized monitoring system. Nucl Instrum Methods Phys Res Sect A 1999;425(1):332-342.

(66) Mishani E, Bonasera TA, Rozen Y, Ortu G, Gazit A, Levitzki A. Fluorinated EGFR-TK inhibitor-based tracers for PET. J Label Compd Radiopharm 1999;42(SUPPL. 1):S27-S29.

(67) Ben-David I, Mishani E, Rozen S. Tert-Butyl Hypofluorite - An Electrophilic tert-Butoxylation Agent. J Org Chem 1998;63(14):4632-4635.

(68) Mishani E, Cristel ME, Dence CS, McCarthy TJ, Welch MJ. Application of a novel phenylpiperazine formation reaction to the radiosynthesis of a model fluorine-18-labeled radiopharmaceutical (18FTFMPP). Nucl Med Biol 1997;24(3):269-273.

(69) Mishani E, Dence CS, McCarthy TJ, Welch MJ. Formation of phenylpiperazines by a novel alumina supported bis-alkylation. Tetrahedron Lett 1996;37(3):319-322.

(70) Rozen S, Mishani E. A novel method for converting aromatic acids into trifluoromethyl derivatives using BrF3. Journal of the Chemical Society, Chemical Communications 1994(18):2081.

(71) Rozen S, Bar-Haim A, Mishani E. Fluorination of Nitro Compounds with Acetyl Hypofluorite. J Org Chem 1994;59(22):6800-6803.

(72) Rozen S, Mishani E, Kol M, Ben-David I. The Chemistry of Methyl Hypofluorite: Its Reactions with Various Unsaturated Centers. J Org Chem 1994;59(15):4281-4284.

(73) Rozen S, Mishani E, Bar-Haim A. A Novel Carbonyl to CF2 Transformation Using BrF3. J Org Chem 1994;59(11):2918.

(74) Rozen S, Bar-Haim A, Mishani E. New Efficient Route to α-Nitro Acids. Oxidation of Amino Acids with HOF·CH3CN. J Org Chem 1994;59(5):1208-1209.

(75) Rozen S, Mishani E. Conversion of esters to α,α-difluoro ethers using bromine trifluoride. Journal of the Chemical Society, Chemical Communications 1993(23):1761-1762.

(76) Appelman EH, French D, Mishani E, Rozen S. Synthesis, Characterization, and Reaction Chemistry of tert-Butyl Hypofluorite. J Am Chem Soc 1993;115(4):1379-1382.

(77) Rozen S, Mishani E, Kol M. A Novel Electrophilic Methoxylation (with a Little Help from F2). J Am Chem Soc 1992;114(20):7643-7645.